WHO Backs Pfizer’s Paxlovid For High-Risk COVID-19 Patients
But Access Obstacles Remain In Lower-Income Countries
An international group of experts has issued new guidance on the use of therapeutics in patients with non-severe COVID-19.
You may also be interested in...
ACT-A, an initiative led by the World Health Organization and involving international health agencies, has significantly improved access to COVID-19 medical countermeasures in lower-income countries. However, further progress could be hindered by a funding shortfall, and ACT-A has urged donors to contribute their fair share.
Following a consultation last year, Medsafe has set new fee levels that take account of both cost-recovery principles and a 4.2% increase in the consumer price index.
The monkeypox cases reported this month are evidence of chains of transmission of the virus, according to the European Centre for Disease Prevention and Control, which says that vaccination of high-risk close contacts should be considered after a benefit-risk assessment.